Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

conciliation from Reported Net Income Available to Common Shareholders and Reported Diluted Earnings Per Common Share to As Reconciled Amounts for Net Income

Available to Common Shareholders and Diluted Earnings per Common Share (unaudited)
(Amounts in Millions, except per share figures)

Three months ended December 31, 2006

Purchase Acquisition- Other

As Accounting Related Specified As

Reported Adjustments Items Items Reconciled

Net sales $2,650 $ - $ - $ - $2,650

Cost of sales 915 - - (45) 870

Selling, general

and administrative 1,250 - - - 1,250

Research and

development 631 - - (15) 616

Acquired in-process

research and

development - - - - -

Other income, net (46) - - - (46)

Special and

acquisition

related charges 12 - - (12) -

Equity income (403) - - - (403)

Income before

income taxes 291 - - 72 363

Income tax expense 87 - - - 87

Net income before

cumulative effect

of a change in

accounting principle $204 $ - $ - $72 $276

Cumulative effect of

a change in

accounting principle,

net of tax - - - - -

Net income $204 $ - $ - $72 $276

Preferred stock

dividends 22 - - -
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2009)...rsity Belfast are developing new sensors to detect... in the fight against the threat of terrorist atta...,swipe, an individual or crime scene to gather a s...ent that can detect the presence of chemicals with...ns to be made in response to terrorist threats. ,...
(Date:11/18/2009)...v. 18 Masimo (Nasdaq: ... Measure-Through Motion and Low-Perfusion pulse ox...i.H.A., one of the largest healthcare Group Purcha...ulti-year purchasing agreement for "gold standard"...t offers preferred contract pricing to Uni.H.A.,s ...
(Date:11/18/2009)...v. 18 /PRNewswire-FirstCall/ - YM BioSciences Inc....uct development company that identifies and advanc... products at various stages of development, announ...ab were presented today in a poster at the 2009 AA...tics conference in Boston, Massachusetts. The repo...
(Date:11/18/2009)...tly reduces key cardiac enzymes at multiple time p...rican Heart Association 2009 Scientific Sessions ,...rapeutics Inc., a biotechnology company pioneering...apeutics derived from pathogens, today reported re...T-111 (Serp-1), an anti-inflammatory protein deriv...
Breaking Biology Technology:New technology detects chemical weapons in seconds 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 3Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 4YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 2Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 3Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 4
...nce at the EuroPCR08 will highlight choice of diff...tegrated imaging platform., SAN DIEGO, and BRUSSE... VOLC ), a leading manufacturer and developer of,i...ment (FM) and Optical,Coherence Tomography (OCT) p...tment of coronary and peripheral vascular disease,...
...ORK and PARSIPPANY, N.J., May 12 Forest,Laborator...al company, and,Daiichi Sankyo, Inc. today announc...reement for AZOR(TM)* (amlodipine and olmesartan m...of two antihypertensives, the,calcium channel bloc...or,blocker olmesartan medoxomil. Forest will recor...
...ference Call at 10:30 a.m. ET, May 13 -, EMERYVIL...Inc. (NTI(R)) (Nasdaq: NTII ) today announced fin...e nine months ended March 31,2008., Revenues for ...llion,compared to $4.9 million for the same three ...ses were $5.9 million for the third,quarter of 200...
Other Biology Technology:Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System 2Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System 3Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System 4Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement 2Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement 3Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement 4Neurobiological Technologies Reports Third Quarter Financial Results 2Neurobiological Technologies Reports Third Quarter Financial Results 3Neurobiological Technologies Reports Third Quarter Financial Results 4Neurobiological Technologies Reports Third Quarter Financial Results 5
(Date:11/20/2009)...Research Center (ERC) has been awarded a grant fro...ethods of recovering and reusing the heat that wou...ression process in a carbon capture system. The go... capture and sequestration, or storage (CCS), and ...emitted into the atmosphere by coal-fired power pl...
(Date:11/19/2009)...which cultivate fungus for food, have many remarka... list: the ant farmers, like their human counterpa...eir gardens grow. The finding, reported this week ...eviously unknown symbiosis between ants and bacter...have come to dominate the American tropics and sub...
(Date:11/19/2009)...A four-year, multi-institutional effort co-led by ...sts culminated today in publication of a landmark ...g in unprecedented detail the DNA sequence of maiz...called by North American consumers, is one of the ...e agricultural crop grown in the United States, re...
Breaking Biology News(10 mins):Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 2Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 3Like humans, ants use bacteria to make their gardens grow 2Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 2Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 4China Pharma Holdings Inc to Report Second Quarter 2009 Financial Results on August 12 2009 53068 1China Pharma Holdings Inc to Report Second Quarter 2009 Financial Results on August 12 2009 53068 2Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America 53066 1Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America 53066 2Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America 53066 3Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America 53066 4Patriot Scientific Corporation Announces Cardiac Science Corporations Purchase of a Moore Microprocessor Patent 28TM 29 Portfolio License 53064 1Patriot Scientific Corporation Announces Cardiac Science Corporations Purchase of a Moore Microprocessor Patent 28TM 29 Portfolio License 53064 2
... young gene known as sphinx is inactivated in the ...courtship, scientists report in the May 27, 2008, ...f Sciences. , High levels of male-male courtship ...sophila melanogaster, the tiny insect that has bee...entury. , In 2002, the research team of Manyuan ...
...mproved resolution, tissue-specific molecular mark...gist James A. Weston and colleagues have possibly ...igin of embryonic cells that give rise to connecti...skull and facial structures in back-boned creature...om the Max Planck Institute of Immunology in Germa...
...ON, Mich.---Armed with chainsaws and pry bars, Uni...es recently hastened the end for nearly 7,000 matu...rm experiment to glimpse the Great Lakes region,s ...m each tree to kill it without cutting it down. , ...Forest Accelerated Succession Experiment (FASET) i...
Other Biology News:Courtship pattern shaped by emergence of a new gene in fruit flies 2Origin of cells for connective tissues of skull and face challenged 2Origin of cells for connective tissues of skull and face challenged 3U-M scientists remove thousands of aspens to glimpse forest's future 2U-M scientists remove thousands of aspens to glimpse forest's future 3
Peptone from Sigma-Aldrich
SmartSpec 3000 Spectrophotometer from Bio-Rad
Propidium Iodide Staining Solution Solution from BD Biosciences Pharmingen
BD Biocoat Matrigel Matrix Thin Layer 35 mm Culture Dishes from BD Biosciences - Discovery Labware
Biology Products: